Isolation of amniotic stem cell lines with potential for therapy

By P. de Coppi, G. Bartsch, M. M. Siddiqui, Tao Xu, Cesar Santos, L. Perin, G. Mostoslavsky, A. Serre, E. Snyder, J. Yoo and 3 more. Nature Biotechnology, 2007

1,937 citations recorded by the source corpus.

Subfields: Genetics, Molecular Biology, Surgery

View Paper: https://www.semanticscholar.org/paper/f96cd8a69a5a23f06a458e777d0dd376d18a6ee3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. M. Kwa
2. C. Herberts
3. H. Hermsen

In Molecular Biology

1. M. Kwa
2. C. Herberts
3. Kelly P. Smith
4. H. Hermsen
5. G. Stein
6. Mai X. Luong

Citations in the corpus

• Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC (2011, background): “A similarly high cellular plasticity for differentiation into the three germ layers has also been described for MSC derived from amniotic fluid (AFMSC) [32], amniotic epithelial cells [22] and endometrial regenerative cells [33].”
• Biomimetic nanofibrous scaffolds for bone tissue engineering (2011, neutral): “Another alternative to ESCs are amniotic fluid-derived stem cells (AFSCs) [76].”
• Endometrial regenerative cells: A novel stem cell population (2007, background): “Adult stem cells derived from tissues such as bone marrow [6], cord blood [7], adipose tissue [8] or the amniotic fluid [9] have demonstrated regenerative potential in a variety of diseases and degenerative disorders, however, these cells types are limited by: availability, invasiveness of extractio”
• Risk factors in the development of stem cell therapy (2011, background): “Considering their features foetal stem cells can be considered a developmental and operational intermediate between ESCs and SSCs [24-27].”
• Mesenchymal Stem Cell Secretome: Toward Cell-Free Therapeutic Strategies in Regenerative Medicine (2017, background): “Our studies have also demonstrated an inhibitory effect of the CM from human uterine cervical stem cells (hUCESC-CM) on monocyte–macrophage differentiation as well as on macrophage–monocyte de-differentiation [25].”
• Scaffolds and cells for tissue regeneration: different scaffold pore sizes—different cell effects (2016, background): “…tissues, umbilical cord, peripheral bloods, dermis, brain, muscle and even tumors (Reynolds and Weiss 1992; Erices et al. 2000; Seale and Rudnicki 2000; Zuk et al. 2001; Roufosse et al. 2004; De Coppi et al. 2007; Haniffa et al. 2007; Huang et al. 2009; Yan et al. 2012; de Sousa et al. 2014).”
• Pluripotency: Toward a gold standard for human ES and iPS cells (2009, background): “Amniotic fluid stem (AFS) cells represent another cell type that display similarities to ES cells (De Coppi et al., 2007).”